Vol. 4 No. 4 (2024): April
Reimbursement Recommendations

Inebilizumab (Uplizna)

decorative image of the issue cover

Published April 2, 2024

Key Messages

  • CADTH recommends that Uplizna be reimbursed by public drug plans for the treatment of neuromyelitis optica spectrum disorder (NMOSD), if certain conditions are met.
  • Uplizna should only be covered to treat adult patients who are anti-aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive and who have had at least 1 NMOSD relapse episode (also known as an “attack”) in the 1 year before initiation, or 2 NMOSD relapse episodes in the 2 years before initiation. Patients must have an Expanded Disability Status Scale (EDSS) score of 8 points or less.
  • Uplizna should only be reimbursed if it is prescribed by neurologists with expertise in treating NMOSD and the cost of Uplizna is reduced to be no greater than the least costly comparator currently reimbursed for the treatment of NMOSD. Uplizna should not be initiated during a NMOSD relapse episode or when used in combination with rituximab, satralizumab, eculizumab, or ravulizumab.